Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

141 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-15

Study Completion Date

2019-06-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

NCT02188173

Macular Edema

COMPLETED

A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated

NCT03953807

Diabetic Macular Edema

COMPLETED PHASE4

Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema

NCT02399657

Diabetes Mellitus Macular Edema Retinal Exudates and Deposits

UNKNOWN PHASE4

Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery

NCT01788475

Diabetic Macular Edema

TERMINATED NA

A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

NCT01445626

Macular Edema

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OZURDEX®

Participants with diabetic macular edema prescribed dexamethasone intravitreal implant, 0.7 mg (OZURDEX®) as per routine clinical practice.

Dexamethasone intravitreal implant

Intervention Type DRUG

Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone intravitreal implant

Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OZURDEX®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant received at least two Ozurdex® implants in the study eye to treat visual impairment due to DME
* First Ozurdex® implant injection occurred after 1 January 2015
* Participant was followed-up at the site for at least 12 months after the first Ozurdex® implant in the study eye